Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Thursday, December 13, 2018 · 471,044,271 Articles · 3+ Million Readers

GeoVax to Present at Three Upcoming Scientific Conferences

/EIN News/ -- Highlighting Progress in HIV, Ebola, Lassa, Zika and Cancer Vaccine Development

ATLANTA, GA, Oct. 18, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that will be represented during presentations at three upcoming scientific conferences.

HIV Research for Prevention (HIVR4P) conference, Madrid, Spain, October 21-25

Paul Goepfert, M.D., University of Alabama, will present results from HVTN 114, a phase 1 trial of GeoVax’s GOVX-B11 preventive vaccine conducted by the HIV Vaccine Trials Network (HVTN).  HVTN 114 was conducted with the support of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

International Society for Vaccines (ISV), Atlanta, Georgia, October 28-30

Arban Domi, PhD, GeoVax Director of Vector Development, will deliver an oral presentation entitled “Development of Vaccines for Infectious Diseases and Cancer Using a Novel MVA-VLP Vector.”  In this talk, Dr. Domi will present preclinical single-dose efficacy data for vaccines against Ebola, Lassa fever and Zika virus, and will discuss GeoVax’s pipeline of other MVA-VLP vaccines in progress, including combination therapy for treatment of Hepatitis B chronic infections and cancers.

World Vaccine Congress - Europe, Lisbon, Portugal, October 29-31

Farshad Guirakhoo, PhD, GeoVax Chief Scientific Officer, will deliver an oral presentation entitled, “MVA-VLP as a Plug and Play platform for development of safe and effective single dose vaccines for Emerging Infectious Diseases, Preclinical data for Zika, Ebola and Lassa as examples”. In this talk, data will be presented that demonstrate the efficacy of GeoVax’s MVA platform-derived vaccines to generate robust, immediate and protective immune responses against a variety of infectious diseases.

David Dodd, GeoVax President & CEO, commented, “We are proud of the vaccine development progress our internal team and external collaborators are making with numerous projects. These upcoming presentations represent our ongoing effort to showcase GeoVax’s technology at various leading scientific and business partnering conferences. These presentations are having the intended results of bringing GeoVax to the attention of the broader vaccine and pharmaceutical communities, generating discussions that have led to some of our current collaborations, and that we expect will continue to pay dividends going forward.”

About GeoVax

GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. GeoVax was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards, a finalist for the 2018 “Best Prophylactic Vaccine” Award for its Zika vaccine at the World Vaccine Congress, as well as a finalist for Pipelines of Promise at Buzz of Bio 2018. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether:  GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax’s vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

GeoVax Labs, Inc.
                    6783847220
                    sreuland@geovax.com

299982_GeoVaxLogo.jpg

Powered by EIN News
Distribution channels:


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release